Top Markets
Coin of the day
MaaT Pharma S.A. MaaT Pharma S.A.

MaaT Pharma S.A.

MAAT
Rangering i aksjer #23616
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on... MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.
Aksjekurs
$3.78
Sist synkronisert: 2026-08-21
Markedsverdi
$71.20M
Endring (1 dag)
2.24%
Endring (1 år)
-43.37%
Land
FR
Handel MaaT Pharma S.A. (MAAT)

Kategori

Utbytteavkastning for MaaT Pharma S.A. (MAAT)
MaaT Pharma S.A. (aksjesymbol: MAAT) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for MaaT Pharma S.A. (MAAT) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
Ikke nok data for de angitte datoene.
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
Selskap Utbytteavkastning Land
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH